Trusted bioanalytical experts to support your trials

13 November 2023

Resolian specializes in providing comprehensive support for bioanalytical assay development, validation, and sample analysis, spanning the entire spectrum from early drug evaluation to clinical trials. The flexibility and agility of Resolian sets it apart, ensuring it can cater to specific demands. In this video, see how it is the right size and shape to adapt to the diverse needs of its clients and how it is committed to evolving and growing to better serve its partners in the world of pharmaceutical research.

This video was filmed at AAPS 2023 PharmSci 360.

Want the latest expert interviews, articles, webinars, virtual summits and more direct to your inbox? Become a SelectScience member for free today>>

SelectScience

- [Vito] Hi, I'm Vito Saccenti, chief commercial officer for Resolian.
- [John] and I'm John Ryan, vice president of Commercial Operations for Resolian.
- Resolian is supporting bioanalytical assay development, validation, and sample analysis. And it really supports from early drug evaluation through to clinical trials.
- And on top of our core services, we also have very well-known DMPK and analytical sciences groups. Our DMPK groups help our clients evaluate candidates early on with in vivo and vitro testing and other services.
And on top of that, our well-known analytical sciences group also helps with a lot of GMP and CMC testing with their materials sciences experts.
- Customers and their drug development programs really come in all shapes and sizes. Is the customer global? Is the trial local or global? How do the partners manage their CROs? Some customers like end-to-end solutions, including central laboratory and biomarker, and others look for trusted specialists in a given area.
That's where Resolian sits, trusted bioanalytical experts to support their clinical trials.
- Resolian has both a global reach as well as regional expertise. We have the same type of core competencies across UK, U.S., China, and Australia, but we also have those regional expertise and locations that enable clients to have great access. We're able to be flexible as well as responsive, but also scale when we need to.
With the transformation of Resolian, I have to give a props to our CEO Pat Bennett and the senior team, because what they've been able to do is build a global team while keeping the experts in the legacy labs, in their place and able to focus on their work and on what they do best. So globally, we've established HR, IT, operations, as well as our business practices in our customer relationship management.
And there's project management down the road. These things that will be harmonized around the existing labs will make it easier for the clients and beneficial for the employees to work and have a harmonized experience.
- Since the announcements and the organization coming together, we've seen a lot of interest from global innovators. So the company is basically scaling up to be ready to support these relationships as they come on board. And with our existing clients, client-based biotechs, we've seen a lot of interest in new areas that we're capable of supporting today that we couldn't in the past.
The global reach of Resolian also retains its regional expertise. While we have the same platforms and core competencies across the UK, U.S., Australia, and China, we also have some real regional expertise and real great access for those clients and those scientists to work together. That makes us a little bit more flexible and a little bit more agile than maybe some of the other players in our field.
Our aim as Resolian is to be a top choice for global partnerships in bioanalysis and analytical sciences.
- This is where the scale, the global reach, and the fact that we're a focused bioanalytical lab is the core.